Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

Inclusion Criteria:

• Participants with a diagnosis of primary SjD for at least 12 months prior to theScreening Visit and meet classification criteria for primary SjS according to the 2016 American College of Rheumatology/ European League Against RheumatismClassification Criteria for Primary Sjogren's Syndrome at the time of screening.

• Participants with moderate to severe systemic disease activity as determined by aclinESSDAI total score ≥ 5 at the Screening Visit.

• Participants are seropositive for antibodies to Sjogren's Syndrome A (SSA)/Anti-Sjogren's Syndrome A (Ro) at the Screening Visit.

• Participants have residual salivary flow as measured by stimulated whole salivaryflow rate ≥ 0.01 milliliters per minute (mL/min) at the Screening Visit.

Additional inclusion criteria are defined in the protocol.

Exclusion Criteria:

• Participants with a diagnosis of secondary SjD, inadequately treated fibromyalgia,other confirmed connective tissue, rheumatic, or systemic inflammatory autoimmunedisease including but not limited to, rheumatoid arthritis, systemic lupuserythematosus, systemic sclerosis, dermatomyositis, or polymyositis, that in theopinion of the Investigator, is likely to interfere with the ability to assessprimary SjD manifestations.

• Participants with a history of clinically significant monoclonal gammopathy,including but not limited to monoclonal gammopathy of undetermined significance,history of multiple myeloma or non-Hodgkin's lymphoma, or have an active malignancyor history of malignancy within 5 years prior to the Screening Visit.

Additional exclusion criteria are defined in the protocol.